Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210768 | 0.86 | TACR1 (0.44) | TACR1KLK7NR1H2NR1H3PARP1 | |
| SCHEMBL35211172 | 0.82 | KLK7 (0.42) | TACR1KLK7NR1H2NR1H3PARP1 | |
| SCHEMBL35210538 | 0.82 | NR1H2 (0.42) | TACR1KLK7NR1H2NR1H3PARP1 | |
| SCHEMBL14199452 | 0.82 | KLK7 (0.47) | TACR1KLK7NR1H2NR1H3PARP1 | |
| SCHEMBL28549464 | 0.79 | PARP1 (0.46) | KLK7NR1H2NR1H3PARP1AGTR2 | |
| SCHEMBL35211212 | 0.78 | TACR1 (0.46) | TACR1NR1H2 | |
| SCHEMBL7301938 | 0.76 | KLK7 (0.47) | KLK7PARP1DPP4 | |
| SCHEMBL7297892 | 0.75 | KLK7 (0.47) | KLK7PARP1KLK5 | |
| SCHEMBL31228493 | 0.75 | KLK7 (0.46) | KLK7NR1H2NR1H3PARP1DPP4 | |
| SCHEMBL31228495 | 0.75 | KLK7 (0.46) | KLK7NR1H2NR1H3PARP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | TACR1 1587/4885KLK7 4653/4885NR1H2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.